Evidence map›Paper›PMID 39737862›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Specific Monitoring the DNA Helicase Function via Anchor-Embedded DNA Probe.

Keni Ning, Xiaoyan Tang, Zhe Li, Liting Zhong, Yingchen Zhou, Jiaen Wang, Wanyi Huang, Han Zhang, Jiajun Ke, Tiangang Luan and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Specific Monitoring the DNA Helicase Function via Anchor-Embedded DNA Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keni NingSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Xiaoyan TangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Zhe LiSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Liting ZhongSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Yingchen ZhouSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Jiaen WangSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Wanyi HuangSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Han ZhangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Jiajun KeSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.
Tiangang LuanSchool of Environmental and Chemical Engineering, Wuyi University, Jiangmen, 529020, China.
Shuo-Bin ChenSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-Sen University, Guangzhou, 510006, China.
Junqiu ZhaiSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.ORCID https://orcid.org/0000-0003-1074-8330

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515030206National Key Research and Development Program of China 2022YFC2805000National Natural Science Foundation of China 22104022National Natural Science Foundation of China 22127810National Natural Science Foundation of China 22377153Natural Science Foundation of Guangzhou City 2024A04J5222Water Resources Science and Technology Innovation Program of Guangdong Province 2011-16
6 · The paper itself

Abstract

DNA helicases play a pivotal role in maintaining genome integrity by unwinding the DNA double helix and are often considered promising targets for drug development. However, assessing specific DNA helicase activity in living cells remains challenging. Herein, the first anchor-embedded duplex (ATED) probe, 17GC, is constructed to uniquely monitor the unwinding activity of Werner syndrome helicase (WRN), a clinical anticancer target. This probe integrates biophysical screening and molecular simulation approaches. The 17GC probe consists of two components: the first one is a bubble structure as an anchor for recruiting WRN in cells, and the second one is GC-rich double helices on both ends of the bubble, which allow high sensitivity in detecting WRN activity. In vitro evaluations demonstrate that 17GC is highly sensitive and specific to WRN (LOD = 33.5 pm) compared to a wide range of other enzymes, including helicases and nucleases. Cellular evaluation reveals that the ATED probe exhibits remarkable performance in monitoring WRN helicase activity and assessing the inhibitory efficiency of clinical WRN inhibitors in various cell types. This study introduces a novel approach for designing specific and sensitive probes for DNA helicases in cells, which holds promise for biological characterization and drug development.

Indexed as

DNA HelicasesDNA ProbesWerner Syndrome HelicaseDNAHumansDNADNA HelicasesDNA ProbesWerner Syndrome HelicaseWRN protein, humanDNA helicasesDNA probeintracellular monitoringWerner syndrome helicase

Identifiers

PMID39737862
PMCPMC11848566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.